Comparative Pharmacology
Head-to-head clinical analysis: HICON versus OSMOLEX ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HICON versus OSMOLEX ER.
HICON vs OSMOLEX ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; possibly involves modulation of hypothalamic thermoregulatory center.
Trihexyphenidyl is a centrally acting anticholinergic agent that blocks muscarinic receptors in the striatum, helping to restore the balance between acetylcholine and dopamine in the basal ganglia, thereby reducing extrapyramidal symptoms.
HICON (norepinephrine) 0.05-0.5 mcg/kg/min IV continuous infusion, titrated to blood pressure.
Initial: 1 mg orally once daily; titrate by 1 mg every 3-5 days based on response and tolerability. Maximum: 8 mg once daily. Administer at bedtime.
None Documented
None Documented
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Terminal elimination half-life is 5-8 hours in healthy adults; prolonged in renal impairment (up to 16 hours in severe impairment).
Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other
Primarily renal (60-80% as unchanged drug and glucuronide conjugates), biliary/fecal (20-40%)
Category C
Category C
Anticholinergic
Anticholinergic/Urinary Antispasmodic